Investor Presentation Full Year 2017

Investor Presentation Full year 2017 Slide 25 Top line growth driven by the diabetes pandemic Novo Nordisk reported quarterly sales Reported sales split by product segments for the full year of 2017 New-generation insulin by therapy Diabetes and obesity Haemophilia² NorditropinⓇ Other GLP-1 diabetes Reported sales Haemophilia CAGR¹: 9.8% Other biopharmaceuticals DKK billion 35 30 25 -2.7% 20 6.3% 15 6.1% 10 11.2% Modern insulin Human insulin Other diabetes care and obesity Growth disorders 2% 6% 8% 9% 6% 40% 5 0 Q4 2007 1 CAGR for 10-year period 2 Haemophilia includes NovoSeven®, NovoThirteen®, NovoEight® and Refixia® changing diabetes 21% 9% Q4 2017 Sales of DKK 111.7 billion (0%) novo nordisk

View entire presentation